Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2026)
Teva Pharmaceutical Industries (TEVA) posted Income from Continuing Operations of 370000000.0 for Q1 2026, down 21.28% on a QoQ basis from 470000000.0 in Q4 2025, and up 68.18% year-over-year from 220000000.0 in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Teva Pharmaceutical Industries' Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 370000000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 68.18% year-over-year to 370000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1553000000.0 (up 217.3% YoY) and the FY2025 annual result came in at 1403000000.0, up 171.58% from the prior year.
- Income from Continuing Operations was 370000000.0 for Q1 2026 at Teva Pharmaceutical Industries, down from 470000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 519000000.0 in Q1 2024 and bottomed at 1796000000.0 in Q4 2023.
- A 5-year average of 273705882.35 and a median of 253000000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 1286.59% — and 2024, when it surged 305.14%.
- Teva Pharmaceutical Industries' Income from Continuing Operations stood at 1334000000.0 in 2022, then tumbled by 34.63% to 1796000000.0 in 2023, then jumped by 84.69% to 275000000.0 in 2024, then soared by 270.91% to 470000000.0 in 2025, then declined by 21.28% to 370000000.0 in 2026.
- Business Quant data shows TEVA's Income from Continuing Operations at 370000000.0 in Q1 2026, 470000000.0 in Q4 2025, and 432000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 370.00 Mn |
| Dec 31, 2025 | 470.00 Mn |
| Sep 30, 2025 | 432.00 Mn |
| Jun 30, 2025 | 281.00 Mn |
| Mar 31, 2025 | 220.00 Mn |
| Dec 31, 2024 | -275.00 Mn |
| Sep 30, 2024 | -393.00 Mn |
| Jun 30, 2024 | -876.00 Mn |
| Mar 31, 2024 | 519.00 Mn |
| Dec 31, 2023 | -1.80 Bn |
| Sep 30, 2023 | 76.00 Mn |
| Jun 30, 2023 | -907.00 Mn |
| Mar 31, 2023 | -253.00 Mn |
| Dec 31, 2022 | -1.33 Bn |
| Sep 30, 2022 | 64.00 Mn |
| Jun 30, 2022 | -278.00 Mn |
| Mar 31, 2022 | -973.00 Mn |
| Dec 31, 2021 | -151.00 Mn |
| Sep 30, 2021 | 306.00 Mn |
| Jun 30, 2021 | 210.00 Mn |